Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Stone

Showing results (521-530 of 544) with videos related to

Pageof 55
Sort By:
Molecular Cancer Therapeutics|July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Cancer Discovery|August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaMarina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
Transfusion|November 24, 2016
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesAlexander B Pine, Eun-Ju Lee, Mikkael Sekeres, et al.
Haematologica|February 4, 2021
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia modelDina Stroopinsky, Jessica Liegel, Manoj Bhasin, et al.
Blood Advances|August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Journal of Geriatric Oncology|June 17, 2023
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemiaP Connor Johnson, Jennifer A Woyach, Angela Ulrich, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Science (New York, N.Y.)|October 29, 2011
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapyTriona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Nature|March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
Pageof 55

Showing results (521-530 of 544) with videos related to

Sort By:
Pageof 55
Molecular Cancer Therapeutics|July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Cancer Discovery|August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaMarina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
Transfusion|November 24, 2016
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesAlexander B Pine, Eun-Ju Lee, Mikkael Sekeres, et al.
Haematologica|February 4, 2021
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia modelDina Stroopinsky, Jessica Liegel, Manoj Bhasin, et al.
Blood Advances|August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Journal of Geriatric Oncology|June 17, 2023
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemiaP Connor Johnson, Jennifer A Woyach, Angela Ulrich, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Science (New York, N.Y.)|October 29, 2011
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapyTriona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Nature|March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
Pageof 55